Climb Bio, Inc. (CLYM)
NASDAQ:CLYM
Want to see CLYM full AI Analyst Report?
CLYM Stock Chart & Stats
$9.16
-$0.15(-7.18%)
At close: 4:00 PM EST
$9.16
-$0.15(-7.18%)
Day’s Range― - ―
52-Week Range$1.16 - $12.48
Previous CloseN/A
Volume51.97K
Average Volume (3M)1.10M
Market Cap
$655.09M
Enterprise Value$739.42M
Total Cash (Recent Filing)$109.56M
Total Debt (Recent Filing)$479.00K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 18, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding57,263,023
10 Day Avg. Volume1,561,525
30 Day Avg. Volume1,100,000
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.98K
Enterprise Value/Ebitda-14.04
Forecast
1Y Price Target
$22.00Price Target Upside140.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt materially lowers solvency and interest burdens for a pre-revenue biotech, preserving flexibility to fund multi-year clinical programs. Low leverage reduces bankruptcy risk and gives management latitude to prioritize R&D investment and strategic partnering without fixed creditor constraints.
Promising Budoprutug Early Clinical DataRobust early efficacy and tolerability in heavily pretreated ITP patients, including durable platelet responses and activity after rituximab, strengthens the clinical case and de-risks the program structurally. Positive translational signals increase the chance of regulatory advancement and competitive positioning across B-cell driven autoimmune indications.
CLYM116 Translational & Dosing AdvantageTranslational pharmacometrics that predict human exposure and dose-dependent IgA suppression support efficient dose selection and a potentially less-frequent dosing profile versus first-generation agents. This structural advantage can lower development risk, improve patient adherence, and differentiate commercial profiles in IgA-driven diseases.
Bears Say
Pre-Revenue With High Cash BurnSustained negative operating and free cash flows create ongoing funding dependence and heighten execution risk for multi-year trials. Elevated cash burn forces frequent capital raises, which can delay development timelines if financing conditions tighten and increases the probability of program slowdowns or prioritization choices.
Equity Erosion & Negative ReturnsMaterially negative ROE and declining equity signal value erosion for shareholders driven by recurring losses and dilution. Until the company achieves revenue or durable margin improvements, returns on invested capital will remain adverse, complicating long-term investor return prospects and raising the bar for future capital allocation.
Reliance On Equity FinancingFrequent reliance on large equity raises and warrants increases dilution risk and creates an overhang that can hamper shareholder value realization. Structural dependence on equity markets can constrain strategic options, require restrictive investor terms, and create misalignment between short-term capital needs and long-term R&D pacing.
Climb Bio News
CLYM FAQ
What was Climb Bio, Inc.’s price range in the past 12 months?
Climb Bio, Inc. lowest stock price was $1.16 and its highest was $12.48 in the past 12 months.
What is Climb Bio, Inc.’s market cap?
Climb Bio, Inc.’s market cap is $655.09M.
When is Climb Bio, Inc.’s upcoming earnings report date?
Climb Bio, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 65 days.
How were Climb Bio, Inc.’s earnings last quarter?
Climb Bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.088.
Is Climb Bio, Inc. overvalued?
According to Wall Street analysts Climb Bio, Inc.’s price is currently Undervalued.
Does Climb Bio, Inc. pay dividends?
Climb Bio, Inc. does not currently pay dividends.
What is Climb Bio, Inc.’s EPS estimate?
Climb Bio, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Climb Bio, Inc. have?
Climb Bio, Inc. has 57,263,023 shares outstanding.
What happened to Climb Bio, Inc.’s price movement after its last earnings report?
Climb Bio, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Climb Bio, Inc.?
Currently, no hedge funds are holding shares in CLYM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Climb Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (140.17% Upside)
$22.00 (140.17% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
793.75%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
-24.09%
Trailing 12-Months
Company Description
Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$22.00
▲(140.17% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
20.12% Insiders
5.46% Mutual Funds
39.82% Other Institutional Investors
31.94% Public Companies and
Individual Investors